PDL BioPharma, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases
PDL BioPharma, Inc. reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases of $20.00 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-15.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases · last filed 2019-03-15
- PDL BioPharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases for the quarter ending 2015-12-31 was $0.00, a 100.00% decline year-over-year.
- PDL BioPharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases for the quarter ending 2015-09-30 was $115.00M.
- PDL BioPharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases for the quarter ending 2015-06-30 was $0.00.
- PDL BioPharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases for the quarter ending 2015-03-31 was $0.00.
- PDL BioPharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases for fiscal 2018 was $20.00M.
- PDL BioPharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases for fiscal 2016 was $59.50M, a 48.26% decline from fiscal 2015.
- PDL BioPharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases for fiscal 2015 was $115.00M, a 41.80% increase from fiscal 2014.
- PDL BioPharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases for fiscal 2014 was $81.10M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases 12 month |
|---|---|---|---|---|
| 2018-12-31 | $20.00M 10-K · filed 2019-03-15 | |||
| 2016-12-31 | $59.50M 10-K · filed 2017-03-01 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-23 | $115.00M derived: sum of 2 quarters · filed 2016-02-23 | $115.00M derived: sum of 3 quarters · filed 2016-02-23 | $115.00M 10-K · filed 2016-02-23 |
| 2015-09-30 | $115.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $115.00M derived: sum of 2 quarters · filed 2015-11-04 | $115.00M 10-Q · filed 2015-11-04 | $180.60M derived: sum of 4 quarters · filed 2015-11-04 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $0.00 10-Q · filed 2015-08-05 | $65.60M derived: sum of 3 quarters · filed 2015-08-05 | $65.60M derived: sum of 4 quarters · filed 2015-08-05 |
| 2015-03-31 | $0.00 10-Q · filed 2015-05-06 | $65.60M derived: sum of 2 quarters · filed 2015-05-06 | $65.60M derived: sum of 3 quarters · filed 2015-05-06 | |
| 2014-12-31 | $65.60M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-23 | $65.60M derived: sum of 2 quarters · filed 2015-02-23 | $81.10M 10-K · filed 2015-02-23 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $15.50M 10-Q · filed 2014-11-10 | ||
| 2014-06-30 | $15.50M 10-Q · filed 2014-08-18 |